ABD WEBINAR SERIES

Pushing the Boundaries in Antibody Discovery

Join industry leaders from Twist Bioscience, Genovac, and Bruker Cellular Analysis in this three-part webinar series exploring the latest advancements in antibody discovery. Gain insights into cutting-edge technologies, market trends, and innovative strategies to accelerate therapeutic development.

Register separately for each session to secure your spot.

April 1, 2025
Webinar 1
A Perspective into Antibody Discovery Market Trends and Transgenic Mouse Performance through Meta-Analysis of over 150 Single B Cell Screening Campaigns
8 AM - 9 AM PST | 11 AM - 12 PM EST
Register Now
April 10, 2025
Webinar 2
Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates
8 AM - 9 AM PST | 11 AM - 12 PM EST
Register Now
April 16, 2025
Webinar 3
Antibody Discovery in 2025: How Industry Leaders are Adapting to Market Trends, Technological Innovations, and Economic Pressures
8 AM - 9 AM PST | 11 AM - 12 PM EST
Register Now
PUSHING THE BOUNDARIES IN ABD | Webinar 1

A Meta-Analysis of 150+ Antibody Discovery Campaigns: Transgenic Mouse Performance Against Single B Cell Technology Trends

Overview

Twist Biopharma Solutions, a division of Twist Bioscience, is a leading expert in antibody discovery, offering best-in-class in vivo, in vitro, and in silico technologies. With 550+ partnered projects, Twist leverages deep biopharma market insights and cutting-edge engineering platforms to maximize success for even the most difficult campaign targets.

This webinar will present a meta-analysis of over 150 completed single B cell screening campaigns, with a focus on membrane-bound targets. Discover how Twist leverages hyperimmune mice and multi-modal antibody characterization on the Beacon® system to enhance immunization strategies, maximize hit rates for new campaigns, and establish baselines for transgenic models in antibody discovery.

Speakers

A smiling man in a red shirt.
Colby Souders, Ph.D.
CSO, Twist Biopharma Solutions
Colby Souders earned his PhD in Cell and Molecular Biology from Texas A&M and previously held positions at Abveris, MassBiologics and Kanyos Bio (now Anokion). At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as develop related platform technologies to advance and expand the MassBiologics pipeline. Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby joined Abveris in 2018 as the Chief Scientific Officer to establish best-in-class antibody discovery workflows and build a premium discovery engine with industry-leading timelines. He continues to hold his role as CSO of Twist Biopharma Solutions after Abveris was acquired by Twist Bioscience in 2021.
A smiling man's face.
Vincent Pai
Director of Product Management, Bruker Cellular Analysis
Vincent Pai is Director of Product Management at Bruker Cellular Analysis. He has over 10 years of expertise in cell biology, nanotechnology, and microfluidics, with research experience from UC San Diego and Massachusetts General Hospital in Boston. He joined Berkeley Lights in 2016 and transitioned through roles as an applications engineer, program manager, and product manager. Following Bruker’s acquisition, Vincent now leads new product development for antibody discovery on the Beacon® optofluidic system.

In Partnership With

A logo with "Twist" in Black block and "biosciences" in small green font.

Live Webcast Details

April 1, 2025
8 AM - 9AM PST | 11 AM - 12 PM EST

Key Takeaways

  • Best-In-Class Antibody Discovery: Learn how a leading service provider leverages the Beacon® system to optimize antibody hits against challenging targets, including membrane-bound and transmembrane antigens.
  • Expertise Through Repeated Success: See how Twist Biopharma Solutions utilizes past campaign performance to optimize immunization strategies and increase success rates.
  • Evaluation of Synergistic Platforms: Understand how historical data can validate the use of transgenic mouse models and new host species (e.g., alpaca, rabbit) for antibody discovery.

Join Us for This Free, Live Webcast

Register Now
PUSHING THE BOUNDARIES IN ABD | Webinar 2

Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates

Overview

Genovac leverages cutting-edge AI-driven in silico humanization, multi-host species screening, and the Beacon® optofluidic system to accelerate antibody discovery. By integrating diverse immune repertoires and advanced discovery platforms, researchers can enhance lead optimization, increase hit diversity, and improve success rates against difficult targets like RAGE.

This webinar will highlight how Genovac's innovative approach streamlines antibody candidate generation, reduces downstream engineering needs, and improves developability profiles. Discover how wild-type host systems, machine learning in lead optimization, and the Beacon® system work together to drive faster, more efficient therapeutic lead development.

Speakers

The face of a smiling blond woman.
Iwona Budnicki, Ph.D.
Manager, Cellular Immunology, Genovac
Iwona Budnicki leads the single B-cell antibody discovery technology group at Genovac where she is responsible for the development of processes on and around Bruker Cellular Analysis’ Beacon platform for the discovery of antibodies against challenging targets. Iwona earned her PhD from the Friedrich-Schiller-University Jena, Germany and has ten years of experience in immunobiology. Her work in the field of T cells and infectious diseases has resulted in several publications in peer-reviewed journals.
The face of a man with dark hair smiling.
Donovan McGinley-Colman
Senior Scientist, Genovac
Donovan McGinley-Colman is a Senior Scientist at Genovac Antibody Discovery. He graduated from North Dakota State University with a Bachelor of Science in Biochemistry. Out of college, he worked for American Preclinical Services supporting PK and E&L studies. Donovan joined Genovac in 2021, where he currently leads implementation and project management pertaining to downstream purification, testing, and characterization through SPR and BLI techniques.
A woman with dark hair in a lab coat smiling
Danielle Borys
Senior Product Applications Scientist, Bruker Cellular Analysis
Danielle Borys is a Senior Product Applications Scientist at Bruker Cellular Analysis. She joined IsoPlexis in 2019 as a senior research associate, and transitioned through scientist roles in research, product development, and client collaborations. Following Bruker’s acquisition, Danielle continues to support proteomic products on the IsoSpark® system and antibody discovery products on the Beacon® optofluidic system.

In Partnership With

Live Webcast Details

April 10, 2025
8 AM - 9 AM PST | 11 AM - 12 PM EST

Key Takeaways

  • Enhanced Antibody Discovery with Multiple Host Species: Learn how leveraging diverse immune repertoires across multiple species improves success rates against difficult targets like RAGE.
  • AI-Powered Humanization & Lead Optimization: Discover how in silico humanization and machine learning accelerate lead identification and developability, reducing downstream engineering efforts.
  • Cutting-Edge Technologies for Faster Antibody Development: Explore how Genovac integrates the Beacon® optofluidic system, wild-type host systems, and advanced discovery platforms to streamline and accelerate antibody discovery and characterization.

Join Us for This Free, Live Webcast

Register Now
PUSHING THE BOUNDARIES IN ABD | ROUNDTABLE

Antibody Discovery in 2025: How Industry Leaders are Adapting to Market Trends, Technological Innovations, and Economic Pressures

Overview

The antibody discovery landscape is evolving rapidly, driven by technological breakthroughs, shifting market trends, and economic pressures that challenge traditional workflows. From AI-driven lead optimization and automation to transgenic models and cell-free expression systems, the industry is transforming how therapeutic antibodies are identified and developed.

Join industry leaders from Twist Bioscience and Genovac for an exclusive roundtable discussion on the most pressing trends in antibody discovery, the impact of financial constraints on R&D strategies, and the cutting-edge innovations shaping the future of antibody therapeutics. Learn how companies are adapting to industry shifts, streamlining operations, and maximizing efficiency while driving scientific advancements.

Speakers

A smiling man in a red shirt.
Colby Souders, Ph.D.
CSO, Twist Biopharma Solutions
Colby Souders earned his PhD in Cell and Molecular Biology from Texas A&M and previously held positions at Abveris, MassBiologics and Kanyos Bio (now Anokion). At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as develop related platform technologies to advance and expand the MassBiologics pipeline.
 
Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby joined Abveris in 2018 as the Chief Scientific Officer to establish best-in-class antibody discovery workflows and build a premium discovery engine with industry-leading timelines. He continues to hold his role as CSO of Twist Biopharma Solutions after Abveris was acquired by Twist Bioscience in 2021.
A man smiling at the camera
Brian Walters
CEO, Genovac
Brian Walters Brian Walters assumed the role of President & CEO of Genovac Antibody Discovery after leading a management-led buyout of Aldevron’s Antibody Discovery Business Unit. Most recently, Brian was serving as President of Aldevron’s Antibody Discovery Business Unit before leading the establishment of Genovac. Brian graduated from the University of Southern Mississippi with a Master of Science in Economic Development and received a Bachelor of Science from the University of North Dakota in Geography and Mathematics.
A smiling man's face.
Vincent Pai
Director of Product Management, Bruker Cellular Analysis
Vincent Pai is Director of Product Management at Bruker Cellular Analysis. He has over 10 years of expertise in cell biology, nanotechnology, and microfluidics, with research experience from UC San Diego and Massachusetts General Hospital in Boston. He joined Berkeley Lights in 2016 and transitioned through roles as an applications engineer, program manager, and product manager. Following Bruker’s acquisition, Vincent now leads new product development for antibody discovery on the Beacon® optofluidic system.

In Partnership With

A logo with "Twist" in Black block and "biosciences" in small green font.

Live Webcast Details

April 16, 2025
8 AM - 9 AM PST | 11 AM - 12PM EST

Key Takeaways

  • Industry Trends & Economic Pressures: Gain insights into how leading companies are navigating financial challenges and adapting strategies to optimize discovery pipelines.
  • Cutting-Edge Technologies & AI: Explore how automation, AI-driven lead optimization, and transgenic models are transforming therapeutic development.
  • The Future of Antibody Discovery: Learn how the Beacon® optofluidic system and other emerging technologies are shaping the next generation of antibody therapeutics.

Join Us for This Free, Live Webcast

Register Now